Grünenthal

This sponsor has funded 10 studies across 6 countries.

PAS funded by this sponsor.
EU PAS ID Status Title Protocol uploaded Results uploaded
14689 Finalised A multicentre, non-interventional, prospective observational study of the use of the sufentanil sublingual tablet system (Zalviso®) for the management... No Yes
15418 Finalised Localised Neuropathic Pain (LNP) managed in the primary care setting in France, Ireland, Italy, Spain, and the United Kingdom: A cross-sectional study... No No
16829 Finalised A multicentre, non-interventional, prospective observational study of the use of the sufentanil sublingual tablet system (Zalviso®) for the management... No Yes
28864 Finalised Opioids prescription in the Valencia Region: Patterns of Use, Misuse and Trends 2011-2017. A Population-based Real World Data Cohort Yes No
31322 Finalised NON-INTERVENTIONAL RETROSPECTIVE EVALUATION OF TOLERABILITY AND EFFICACY OF THE ATYPICAL WHO-STEP III OPIOIDANALGESIC TAPENTADOL PR UNDER REAL-WORLD... No No
32754 Finalised NON-INTERVENTIONAL RETROSPECTIVE EVALUATION OF TOLERABILITY AND EFFICACY OF TYPICAL ORAL LONG-ACTING WHO-STEP III OPIOID ANALGESICs UNDER REAL-WORLD... No No
32826 Ongoing Efficacy and tolerability of a 5% lidocaine medicated plaster in adult patients with localized neuropathic pain: a retrospective analysis of... No No
38332 Finalised A real world evidence study from Germany on the safety and efficacy of tapentadol and typical oral long-acting opioid analgesics in chronic low back... No No
47913 Planned Characteristics, Treatment and Healthcare Resource Utilisation in Patients diagnosed with Neuropathic or Chronic Pain Using Primary Care Electronic... No No
107501 Finalised Pain characteristics of patients recommended total knee arthroplasty due to painful osteoarthritis – a cross-sectional analysis of depersonalized... No No

PAS by Risk Management Plan (RMP) requirement

Grünenthal

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.